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Aims Mesenchymal stem cells (MSCs) arewidely used for cell therapy, particularly for the treatment of ischaemic heart disease.
Mechanisms underlying control of their metabolism and proliferation capacity, critical elements for their survival and
differentiation, havenot been fully characterized.AMP-activatedprotein kinase (AMPK) is a key regulator knownto meta-
bolically protect cardiomyocytes against ischaemic injuries and, more generally, to inhibit cell proliferation.
We hypothesized that AMPK plays a role in control of MSC metabolism and proliferation.
Methods
and results
MSCs isolated from murine bone marrowexclusively expressed the AMPKa1 catalytic subunit. In contrast to cardiomyo-
cytes, a chronic exposure of MSCs to hypoxia failed to induce cell death despite the absence of AMPK activation. This
hypoxic tolerance was the consequence of a preference of MSC towards glycolytic metabolism independently of
oxygen availability and AMPK signalling. On the other hand, A-769662, a well-characterized AMPK activator, was able
to induce a robust and sustained AMPK activation. We showed that A-769662-induced AMPK activation inhibited
MSC proliferation. Proliferation was not arrested in MSCs derived from AMPKa1-knockout mice, providing genetic evi-
dence that AMPK is essential for this process. Among AMPK downstream targets proposed to regulate cell proliferation,
we showed that neither the p70 ribosomal S6 protein kinase/eukaryotic elongation factor 2-dependent protein synthesis
pathway nor p21 was involved, whereas p27 expression was increased by A-769662. Silencing p27 expression partially
prevented the A-769662-dependent inhibition of MSC proliferation.
Conclusion MSCs resist hypoxia independently of AMPK whereas chronic AMPK activation inhibits MSC proliferation, p27 being
involved in this regulation.
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1. Introduction
Trials of mesenchymal stem cell (MSC) transplantation into infarcted
myocardium have demonstrated positive effects on recovery of
cardiac function.1,2 The therapeutic efficacy of MSCs is closely related
to their survival capacity in hypoxic/infarcted regions where they
are transplanted and to their ability to trans-differentiate into
cardiomyocyte-like cells. Therapeutic benefit has been demonstrated
when stem cells are cultured under hypoxia prior to transplantation.3
We hypothesized that targeting AMP-activated protein kinase
(AMPK), an enzyme involved in hypoxic tolerance, cell proliferation,
and differentiation, could increase the efficacy of stem cell therapy.
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AMPK is a heterotrimeric protein kinase composed of one catalytic (a)
and two regulatory (b/g) subunits existing as several isoforms.4,5 Cellular
energy imbalance, observed during myocardial ischaemia, and the result-
ing increase in an intracellular AMP/ATP ratio promote AMPK activa-
tion.5–7 Ischaemia-mediated AMPK activation mainly arises from its
phosphorylation on Thr172 by LKB1.8 Once activated, AMPK functions
to maintain cellular energy balance by switching on catabolic pathways
while switching off anabolism.5,6 This re-establishes energy balance and
enhances cell survival in the absence of oxygen. Genetic inactivation of
the cardiac AMPKa2 isoform elicits energetic imbalance accompanied
by rapid and severe ischaemic contracture.9 Similar results have been
obtained using mouse expressing a kinase-dead form of AMPK.10 Inde-
pendently of changes in energy charge, AMPK can be phosphorylated
on Thr172 by Ca2+/calmodulin-dependent kinase kinase-b (CaMKKb)
in response to elevation of cytosolic [Ca2+],11 which is involved in the
regulation of non-metabolic processes, such as smooth muscle contrac-
tion and cytoskeleton organization.12,13 These non-metabolic functions
include the stimulation of mitochondrial biogenesis and the inhibition
of cell proliferation. AMPK is known to induce expression of the
proliferator-activated receptor gamma coactivator-1a (PGC1a), a regu-
lator of mitochondrial biogenesis.14 The importance of mitochondrial
biogenesis is obvious for cardiac differentiation of MSCs, because these
cells are characterized by immature mitochondria.15 Concerning cell
proliferation, AMPK activation in mouse embryonic fibroblasts results
in p53 phosphorylation, which induces the expression of p21, an inhibitor
of cell cycle progression.16 Moreover, AMPK activation in cancer cells
suppresses theirproliferationbyelevating levelsof the cell cycle inhibitory
protein p27.17 AMPK is also known to inhibit the mammalian target of
rapamycin/p70 ribosomal S6 protein kinase (p70S6K) and eukaryotic
elongation factor 2 (eEF2) signalling pathways, involved in the down-
regulation of protein synthesis and cell growth.6,7 All these aspects are
crucial because suppressed cell proliferation has been shown to favour
differentiation and vice versa. Indeed, the overexpression of Cyclin D1,
a positive cell cycle regulator, inhibited myogenic differentiation.18 Con-
versely, p27 overexpression in intestinal epithelial cells leads to an
increase in differentiation markers.19 Finally, an interactomic study has
demonstrated that expression of the proliferation-linked protein
network is negatively correlated with that of differentiation.20
Given that AMPK: (i) controls cardiomyocyte survival under hypoxia,
(ii) inhibits cell proliferation, and (iii) increases mitochondrial biogenesis,
we hypothesized that AMPK is a key target for improving MSC deploy-
ment in cardiac stem cell therapy. In the present study, we initially char-
acterized AMPK isoform expression and pharmacological activation in
MSCs in comparison with adult cardiomyocytes. We then investigated
AMPK’s role in the control of MSC survival under hypoxia, in MSC
proliferation, and in mitochondrial biogenesis.
2. Methods
For a detailed description, see the expanded materials and methods
section in Supplementary material online.
2.1 Ethics statement
All animal studies were approved by the Animal Research Committee of
Universite´ catholique de Louvain (Approval ID: UCL/MD/2007/049)
and performed in agreement with guidelines on animal experimentation
at our institution (UCL). This study conforms to the Guide for the Care
and Use of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85-23, revised 1996).
2.2 Isolation and culture of adult
cardiomyocytes and MSCs
Animals were anaesthetized with ketamine/xylazine (i.p., 80/10 mg/kg)
and sacrificed by cervical dislocation before removing tissues. Anaesthe-
siadepthwasmonitoredby limbwithdrawal using toepinching.Cultured
cardiomyocytes were processed as described previously.21 Cultured
mouse MSCs were prepared according to a protocol designed for rat
MSCs.22 Quality of the MSC preparations was evaluated by measuring
the expression of height-different surface antigens (see Supplementary
material online for details). They were positive for CD29 and CD44 and
negative for CD11b/CD45/CD34/CD31/CD117. The differentiation
capacity of MSCs was also verified (see Supplementary material
online, Figure S1). Silencing experiment protocol is described in Supple-
mentary material online.
2.3 Cell treatment and lysis
Cells were treated as described in figure legends. After treatment, the
medium was removed and the cells were lysed in ice-cold lysis buffer
containing 50 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
(pH 7.5), 50 mM potassium fluoride, 1 mM potassium phosphate,
5 mM ethylene diamine tetraacetic acid, 5 mM ethylene glycol tetraace-
tic acid (EGTA), 15 mM b-mercaptoethanol, complete protease inhibi-
tor (Roche), 1 mM vanadate, and 1% (vol/vol) Triton X-100. The lysates
were then centrifuged (10 000 g, 15 min, 48C), and the supernatants
stored at 2808C. Cell fractionation is detailed in Supplementary
material online.
2.4 Detection and quantification of total
and phosphorylated proteins
The antibodies deployed to evaluate the protein levels of AMPK iso-
forms, acetyl-CoA carboxylase (ACC), Histone H3, p27 and eEF2, and
the phosphorylation state of Thr172 AMPKa, Ser79 ACC, Thr389
p70S6K, Thr56 eEF2, and Ser10 H3 are described in Supplementary
material online. Immunoblots were quantified after normalization (see
Supplementary material online).
2.5 Metabolite concentrations and oxygen
consumption rate
Lactate production, adenine nucleotides, and oxygen consumption rate
(OCR) were measured as described in Supplementary material online.
2.6 Cell proliferation, cell cycle distribution,
cell death, and apoptosis
MSC proliferation capacity and cell cycle distribution were tested by
direct DNA synthesis measurement using 5-ethynyl-2′-deoxyuridine
and propidium iodide, respectively. Viable, necrotic, and apoptotic
MSCs were identified by the fluorescent dye Annexin V-fluorescein
isothiocyanate apoptosis detection kit (Sigma). Adult necrotic cardio-
myocytes were detected by incubation with 50 mM propidium iodide.23
2.7 Protein synthesis
Cells were incubated for 48 h with [14C]l-phenylalanine (0.75 mCi/mL)
in the presence and absence of A-769662. They were then lysed and
incubated with 10% trichloroacetic acid for 20 min at 48C to precipitate
proteins. Precipitated material was neutralized with 100 mM NaOH.
The samples were precipitated a second time with 10% trichloroacetic
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acid for 20 min at 48C. After re-suspension of protein pellets in formic
acid, incorporated radioactivity was measured by liquid scintillation.
2.8 Quantitative PCR
Quantitative PCR (qPCR) was performed as described in Supplemen-
tary material online. mRNA levelswere expressed relative to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH). Relative changes in the
target gene-to-GAPDH mRNA ratio were measured according to the
formula 2−DDCt.
2.9 Protein measurement and statistics
Protein content was estimated by the Bradford method with bovine
serum albumin as standard. The results are expressed as means+ SE.
Statistical significance was calculated by two-tailed unpaired Student’s
t-test and one-way analysis of variance with the Bonferroni post hoc
test for simple and multiple comparisons, respectively.
3. Results
3.1 AMPK expression and activation
in MSCs
We defined the expression profiles of AMPK catalytic (a) and regulatory
subunits (b and g) in MSCs. While adult cardiomyocytes express both
AMPKa1 and AMPKa2 isoforms, we found that MSCs exclusively
express AMPKa1 (Figure 1A). Both AMPKb1 and AMPKb2 isoforms
were detected in MSCs and cardiomyocytes (Figure 1B). Finally, MSCs
expressed AMPKg1 and slightly AMPKg2 (see Supplementary material
online, Figure S2). Collectively, we observed that MSCs mainly express
Figure 1 Differential expression of AMPK subunits (A and B) and effect of AMP-dependent (C) or calcium-dependent (D–F ) AMPK activators and
A-769662 (G) on AMPK and/or ACC phosphorylation state in MSCs. (A and B) MSC extracts were blotted to identify the AMPK subunits expressed.
C+ (control) represents extracts of the mouse heart (A) and adult rat cardiomyocytes (B). (C) MSCs were incubated with oligomycin (1 mM) or phenformin
(0.5 mM) for 15–120 min. Controls were cardiomyocytes incubated with (C+) or without (C2) oligomycin (1 mM, 60 min). (D and E) MSCs were incu-
bated with A23187 (10 mM) for 5–40 min alone or in combination with ethylene diamine tetraacetic acid (EGTA) (5 mM) or STO-609 (10 mM). (F) MSCs
were incubated with endothelin-1 (20 nM) for 2–20 min alone or in combination with STO-609 (10 mM). (G) MSCs were incubated with A-769662 for
5 min to 24 h. Supernatants of MSC lysates were immunoblotted. eEF2 served as a loading control and was evaluated on the same blot after stripping. The
blots are representative of at least three different experiments.
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AMPKa1b1g1 and AMPKa1b2g1 complexes. Two upstream kinases of
AMPK, LKB1 and CaMKKb, were detected in cell lysates derived from
MSCs (data not shown).
Oligomycin and phenformin, which cause ATP depletion by poisoning
mitochondria, are known to promote AMPK activation in cardiomyo-
cytes.21 However, neither oligomycin nor phenformin induced AMPK
phosphorylation in MSCs (Figure 1C), correlating with the absence of
energy depletion as assessed by measuring the AMP/ATP ratio (see
Supplementary material online, Figure S3). In contrast, the calcium iono-
phore A23187 and endothelin-1, both known to increase cytosolic
Ca2+ concentration, promoted transient AMPK phosphorylation
(Figure 1D–F). It also correlated with increased phosphorylation of
ACC, a bona fide substrate of AMPK (Figure 1F). AMPK and ACC phos-
phorylation was blunted by the calcium chelator EGTA and/or by
STO-609, a selective CaMKK inhibitor (Figure 1E and F). We finally
tested the A-769662 compound, known to directly stimulate AMPK
Figure 2 Effect of hypoxia on AMPK and ACC phosphorylation state (A and B), on cell survival (C ), lactate production in adult cardiomyocytes (D) and
MSCs (E), and Glut1 and iPFK2 expression in MSCs (F). Adult rat cardiomyocytes (ARCMs) and MSCs were submitted to different periods of normoxia or
hypoxia. (A–B) Immunoblots evaluating AMPK and ACC phosphorylation representative of at least three experiments. Positive controls were oligomycin-
treated cardiomyocytes and A23187-treated MSCs. ACC phosphorylation wasquantified and presented relative to positive controls (C+). Forcardiomyo-
cytes, two blots performed in parallel were required to compare the elevated number of samples, but aliquots of the same positive control were used in
each blot to allow comparisons. Values are the means+ SE. (C) Cell survival was evaluated after 24 and 17 h of incubation for MSCs and ARCMs, respect-
ively. (D and E) ARCMs and MSCs were incubated for the indicated periods of normoxia (open circles) or hypoxia (solid circles). Lactate production rates
are indicated in boxes. (F) Glut1 and iPFK2 mRNA expression in MSCs were quantified by qPCR after 24 h of treatment. Values are relative to normoxia.
Values are the means+ SE of at least three experiments. *P ≤ 0.05 vs. corresponding normoxia-treated cells.
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through its binding to AMPKb1.24–26 A-769662 induced sustained AMPK
and ACC phosphorylation at the frequently administered concentration
of 100 mM (Figure 1G).
3.2 Differential effect of hypoxia on
MSCs and cardiomyocytes
MSCs were subjected to hypoxia to mimic injection in hypoxic/ischaemic
tissueduring cardiac cell therapy. The impactofhypoxiaonAMPKactivity,
cell survival, and metabolism was assessed. MSCs were compared with
cardiomyocytes where both AMPK and ACC started to be phosphory-
lated after 2 h of hypoxia (Figure 2A). In MSCs, neither AMPK nor ACC
phosphorylation was altered in response to hypoxia, even after 48 h
(Figure 2B). Cardiac AMPK activation by hypoxia is known to result
from both ATP decline and AMP increase.27 The absence of AMPK activa-
tion inMSCs correlatedwith themaintenanceofATPconcentration (nor-
moxia: 19.9+1.5; 24 h hypoxia: 19.4+2.9 nmol ATP/mg protein, not
significant—NS). Similarly, AMP remained unchanged throughout
hypoxia (normoxia: 4.7+0.7; 24 h hypoxia: 6.2+1.8 nmol AMP/mg
protein, NS). Conservation of energetic balance during hypoxia corre-
lated with the maintenance of MSC survival (Figure 2C). Cardiomyocytes
were more sensitive to the absence of oxygen. Indeed, while AMPK acti-
vation contributed to the protection of cardiomyocytes during the first
period of hypoxia (normoxia: 82.5+2.2 vs. hypoxia 2 h: 80.5+1.0%
of living cells, NS), cell death increased two-fold after 17 h of hypoxia
(Figure 2C). To explain the high resistance of MSCs to hypoxia, their me-
tabolism was evaluated by measuring lactate production, the end product
of anaerobic glycolysis, and the main ATP provider during hypoxia. No
lactate accumulation was seen in normoxic cardiomyocytes, indicating
their exclusive oxidative metabolism (Figure 2D). Lactate production oc-
curred under hypoxia, revealing a shift towards anaerobic metabolism
(Figure 2D). In contrast, normoxic MSCs produced lactate at a rate
similar to that in hypoxic cardiomyocytes (Figure 2E), demonstrating
that MSCs are mainly glycolytic in basal condition. Lactate production
by MSCs was further enhanced under hypoxia (Figure 2E). Anaerobic
stimulation correlated with the increased expression of two critical glyco-
lytic regulators, namely glucose transporter Glut1 and inducible
6-phosphofructo-2-kinase (iPFK2; Figure 2F), as described in cancer
cells.28 The glycolytic dependence of MSCs was confirmed by performing
glucose deprivation (see Supplementary material online, Figure S4). The
absence of glucose induced energetic imbalance (increase in the AMP/
ATP ratio) and reduced MSC survival. The increase in the AMP/ATP
ratio being accompanied by the activation of the AMPK pathway demon-
strates the ability of AMPK to be activated in an AMP/LKB1-dependent
manner.
3.3 Effect of AMPK activation on MSC
proliferation
We investigated the effect of AMPK activationon MSC proliferation. We
tested A-769662 as it causes sustained AMPK activation (Figure 1G).
A-769662 significantly decreased the MSC proliferation rate both in
the presence or in the absence of serum (Figure 3A). This correlated
with a decreased cell number in the S and G2 phases (Figure 3B). The five-
fold decline of Cyclin D1 expression and the two-fold reduction of
Histone H3 phosphorylation, both being proliferation markers, con-
firmed the inhibitionofMSCproliferation (Figure3CandD). Interestingly,
cell cycle inhibition was not associated with increased cell death
(Figure 3E) and was reversed by A-769662 washout (Figure 3F).
AMPKa1 is the sole AMPK catalytic isoform detectable in MSCs. We
isolated MSCs from AMPKa1-knockout (KO) mice to confirm the role
of AMPK in A-769662-induced arrest of proliferation. AMPKa1 was
absent, and there was no detectable compensation by AMPKa2
(Figure 4A). A-769662-dependent ACC phosphorylation was severely
blunted in AMPKa1KO-derived MSCs, confirming the loss of AMPK
Figure 3 Effect of A-769662 on MSC proliferation (A), cell cycle
(B), Cyclin D1 expression (C), Histone H3 phosphorylation state
(D), cell survival (E), and effect of A-769662 washout (F ). MSCs were
incubated with (solid bar) or without (open bar) A-769662
(100 mM). (A) MSCs were incubated in the presence or absence
of 1% FBS, and proliferation state was measured after 48 h of
treatment. (B) Cell cycle S and G2 phases were evaluated after 48 h
of treatment. (C and D) Cyclin D1 mRNA expression and Histone
H3 phosphorylation state were quantified after 24 h of incubation.
Values are relative to untreated cells. (E) Cell survival was evaluated
after 24 or 48 h of treatment. (F) MSCs were incubated with
A-769662 for 48 h, and then A-769662 was removed or not. Values
are the means+ SE of at least three different experiments. *P ≤ 0.05.
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activity (Figure 4B). In line with the anti-proliferative action of AMPK,
AMPKa1KO-derived MSCs manifested two-fold greater proliferation
capacity than wild-type (WT) MSCs under basal condition (Figure 4C).
We incubated both MSC populations with escalating concentrations
of A-769662 (Figure 4D). At lower concentrations (12.5 and 25 mM),
A-769662 inhibited proliferation of WT MSCs, whereas it had no
effect in AMPKa1KO-derived MSCs, confirming the essential involve-
ment of AMPK in A-769662 action. The inhibitory effect of A-769662
at lower concentration was further confirmed by evaluating the distribu-
tion of MSCs under the different cycle phases (see Supplementary ma-
terial online, Figure S5), but was independent of Cyclin D1 whose
expression was not modulated (data not shown).
Unexpectedly, A-769662 was still able to block AMPKa1KO-derived
MSC proliferation at higher concentration. This could derived from cell
death that occurred in the absence of AMPK (see Supplementary mater-
ial online, Figure S6) and revealed an AMPK-independent action of the
compound at this concentration.
We identified the molecular mechanism by which A-769662-
mediated AMPK activation inhibits cell proliferation, by examining
known AMPK downstream targets: p70S6K, eEF2, p21, and p27
(Figure 5). p70S6K phosphorylation was suppressed by the highest con-
centration of A-769662 in WT MSCs, and this inhibition almost com-
pletely disappeared in AMPKa1KO-derived MSCs (WT: 73+15 vs.
KO: 22+ 7% of inhibition, P ≤ 0.05). However, lower A-769662
concentrations did not affect p70S6K phosphorylation in WT MSCs,
ruling out p70S6K involvement in the AMPK-specific action of
A-769662 on cell proliferation. Similarly, eEF2 phosphorylation (corre-
sponding to its inhibition) occurred in A-769662-treated WT cells and
not in AMPKa1KO-derived MSCs. This AMPK-mediated inhibition
was statistically significant at 25 and 100 mM, but not at 12.5 mM,
where arrest of proliferation had already occurred. To definitively
exclude a role of p70S6K or eEF2 in A-769662 action, we evaluated
the protein synthesis rate. Protein synthesis, although reduced at
100 mM, was not impacted by lower A-769662 concentrations (see Sup-
plementary material online, Figure S7). Concerning cell cycle, p21 and
p27 expression were enhanced by A-769662 in WT MSCs, and this in-
crease was abolished by AMPKa1 deletion (Figure 5C and D). However,
only p27 expression was increased by low concentrations of A-769662,
stimulation of p21 expression being only observed at 100 mM. We
further confirm the role of p27 by silencing its expression (Figure 5E–
G). A reduction of 50% in p27 expression increased the basal prolifer-
ation rate of MSCs, demonstrating the role of p27 in this process
(Figure 5E and F ). Furthermore, the silencing of p27 expression
induced a 50% reduction in the inhibitory action of A-769662 on MSC
proliferation (Figure 5G and Supplementary material online, Figure
S8A). From these results, we can conclude that p27 is, at least partially,
involved in the AMPK-specific action of A-769662 on MSC proliferation.
It must be noted that the increase in p27 expression induced by AMPK
Figure4 Effect of A-769662 treatment on ACC phosphorylation state and on the proliferationof WTand AMPKa1KO-derived MSCs. (A) Expressionof
differentAMPKa isoforms. Positive controls (C+) represented extracts of adult rat cardiomyocytes. (B) WTand AMPKa1KO-derivedMSCs wereexposed
to different concentrations of A-769662 for 1 h. Cell lysates were then analysed by immunoblotting phosphorylated ACC. Values are relative to respective
untreated MSCs. (C) Basal proliferation rate of WT and AMPKa1KO-derived MSCs. (D) Effect of A-769662 on proliferation capacity of WT and
AMPKa1KO-derived MSCs. Values are relative to respective untreated cells. Values are the means+ SE of at least three different experiments.
*P, 0.05 vs. respective controls.
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resulted in its accumulation in the cytoplasm rather than in the nucleus
(see Supplementary material online, Figure S8B).
3.4 Effect of AMPK activation on markers
of mitochondrial biogenesis
Next, we tested if AMPK activationwas sufficient to initiate mitochondrial
biogenesis in MSCs (Figure 6). Both low and high concentrations of
A-769662 increased PGC1a expression in WT, but not in AMPKa1WT-
derived MSCs. A similar expression profile was assigned to mitochondrial
transcription factor A (mtTFA), a PGC1a downstream target involved in
mitochondrial DNA replication. However, a 5-day incubation with
A-769662 is not sufficient to increase the mitochondrial OCR of MSCs
(Figure 6C and Supplementary material online, Figure S9).
4. Discussion
We investigated: (i) the role of AMPK in the regulation of MSC metab-
olism under hypoxic conditions and (ii) the impact of AMPK activation
on MSC proliferation capacity and mitochondrial biogenesis.
4.1 Comparison between MSCs and
cardiomyocytes in terms of AMPK isoform
expression and pharmacological activation
Whereas cardiomyocytes express the catalytic isoforms AMPKa1/a2,
MSCs exclusively express AMPKa1. Knowing thatAMPKa2 is important
for the control of cardiac metabolism under ischaemia,9 the shift from
Figure 5 Effect of A-769662 treatment on p70S6K (A) and eEF2 (B) phosphorylation state, p21 mRNA expression (C ) and p27 expression (D) in WT
and AMPKa1KO-derived MSCs, and effect of siRNA-mediated p27 silencing on its expression (E) and on MSC proliferation under basal (F )
or A-769662-treated conditions (G). Values are relative to respective untreated cells (A–D, G) or cells transfected by control siRNA (scramble, Scr)
(E and F ) and are the means+ SE of at least three different experiments. *P, 0.05 vs. respective controls.
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AMPKa1 to AMPKa2 could be a critical step in the differentiation
process of MSCs to (pre)cardiomyocytes.
In MSCs, AMPK can be easily activated through a Ca2+-dependent
pathway. This was expected knowing that AMPKa1 is particularly sensi-
tive to this pathway.29 In contrast, mitochondrial inhibitors, oligomycin
and phenformin, that activate AMPK via an increased AMP/ATP ratio
did not induce AMPK activation despite the presence of LKB1. This cor-
related with the absence of changes in the AMP/ATP ratio, which could
be linked to the low activity of immature MSC mitochondria.30
However, the AMP-mediated/LKB1-dependent pathway is functional,
because glucose deprivation was able to activate AMPK. Finally, we
showed that A-769662 efficiently activated AMPK in MSCs. A-769662
is of particular interest, because: (i) it directly binds to AMPK in contrast
to other agents that act indirectly via AMP or Ca2+ and (ii) its action on
AMPK persists for at least 2 days.
4.2 MSCs are resistant to hypoxia
independently of AMPK
AMPK controls cardiac metabolism and participates in cardiomyocyte
survival under ischaemia/hypoxia.6 In contrast, our study revealed that
AMPK does not play a role in the regulation of energy homeostasis in
hypoxic MSCs. Indeed, chronic hypoxia did not activate AMPK in
these cells. The absence of AMPK activation was linked to the lack of
ATP decline and AMP accumulation. The metabolic resistance of
MSCs to hypoxia indicates their independence from oxygen. This was
confirmed by their efficient cell survival in the absence of oxygen,
even if AMPK was not activated. Our results are in agreement with a
recent study by Deschepper et al.,31 comparing hypoxia in the presence
and absence of glucose. They demonstrated that MSC death may occur
under very long-term hypoxia exposure due to progressive glucose
deficiency and not hypoxia per se. To understand the peculiar resistance
of MSCs to hypoxia, we compared their metabolism with that of cardi-
omyocytes that typically shift from exclusive oxidative to glycolytic me-
tabolism under hypoxia. The augmented production of lactate by MSCs
undernormoxia reveals that theyaremainly glycolytic, producingenergy
independently of mitochondria and oxygen. Similar glycolytic status,
which can be explained by the absence of mature mitochondria, and
resistance to hypoxia have been also found in inducible pluripotent, em-
bryonic, and/or neural progenitor stem cells.15,32– 34 It can be linked to
the Warburg effect observed originally in cancer cells, where enhanced
glycolysis is required to support cell proliferation.35 MSC glycolysis is
further increased under hypoxia via the up-regulated expression of
Glut1 and iPFK2. In terms of cardiac cell therapy efficacy, the glycolytic
characteristic of MSCs makes them resistant to transplantation in
hypoxic areas independently of AMPK. However, once differentiated
into oxidative (pre)cardiomyocytes, they should become sensitive to
hypoxia. In this context, AMPK activation should induce protection, as
for adult cardiomyocytes.
4.3 Sustained AMPK activation inhibits
MSC proliferation
We showed that AMPK activation by A-769662 promoted MSC prolif-
eration arrest without affecting viability. A-769662 blocked DNA syn-
thesis and decreased the percentage of cells in the S/G2 phases. Cell
cycle inhibition by the non-specific AMPK activators, AICAR and met-
formin, was discerned previously in various cell types, such as
glioma,17 neuronal stem,36 and acute myeloid leukaemia cells.37 Inverse-
ly, the expression of constitutively active AMPK reduced the growth of
embryonic fibroblasts.16 To the best of our knowledge, we are the first
todemonstrate theanti-proliferativecapacityofA-769662onstemcells.
By charting dose–response curves and studying AMPK-deleted MSCs,
we also demonstrated that neither p70S6K/eEF2 nor p21 was involved
in the AMPK-dependent anti-proliferative action of A-769662. In con-
trast, A-769662, at lower concentrations, increased p27 expression
and inhibited cell proliferation, both disappearing in AMPKa1KO-
derived MSCs. Experiments performing p27 knock-down confirmed
the role of this protein in the AMPK-mediated MSC cycle arrest. The
link between AMPK, p27, and proliferation has been already investi-
gated.38– 40 The AMPK phosphorylation of p27 increases its stability
and induces its accumulation in the cytoplasm.38 This promotes autop-
hagy that can be directly linked to cell proliferation inhibition.39,40
Knowing that p27 accumulates in the cytoplasm of A-769662-treated
Figure 6 Effect of A-769662 treatment on PGC1a (A) and mtTFA
(B) expression and on mitochondrial (mt) OCR (C). Cells were
treated with A-769662 during 24 h (A and B) or 5 days (C). For A and
B, values are the means+ SE of at least three different experiments.
*P, 0.05. For C, values are shown as means+ SE of eight samples
and are representative of three independent experiments.
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MSCs, we could speculate that a similar autophagic process occurred in
our model.
As a future prospect and as shown previously for the differentiation of
intestinal epithelial cells,19 it would be interesting to see if such inhibition
of proliferation favours MSC differentiation into cardiomyocytes in the
presence of a differentiation cocktail. Our results are reinforced by a
recent study disclosing thatAMPK fosters the differentiation of endothe-
lial progenitor cells.41
4.4 A-769662 increases the expression of
components of mitochondrial biogenesis
ThepresentworkalsoshowedthatA-769662 led toanAMPK-dependent
increase in PGC1a and mtTFA expression. Both are major elements of
mitochondrial biogenesis, which couldparticipate in the maturationof im-
mature mitochondria necessary for transition from glycolytic to oxidative
metabolism characteristic of MSCs differentiated into cardiomyocytes.
However, we showed that AMPK activation alone is not able to shift
MSC from glycolytic to oxidative metabolism, the presence of a complete
differentiation cocktail being probably necessary.
5. Conclusions
Here, we report that: (i) undifferentiated MSCs, characterized by glyco-
lytic metabolism, are particularly resistant to hypoxia independently of
AMPK; (ii) pharmacological activation of AMPK by A-769662 reduces
MSC proliferation via the regulation of p27 expression; and (iii)
A-769662 treatment increases mitochondrial biogenesis via an AMPK-
dependent pathway.
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